Dr. Robin A. Lacour, MD
Claim this profileMcKee Medical Center
Studies Endometrial Cancer
Studies Gastroesophageal Junction Adenocarcinoma
5 reported clinical trials
10 drugs studied
Area of expertise
1Endometrial Cancer
Stage III
Stage IV
HER2 positive
2Gastroesophageal Junction Adenocarcinoma
Stage III
Stage IV
HER2 positive
Affiliated Hospitals
Clinical Trials Robin A. Lacour, MD is currently running
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting1 award Phase 2 & 3
Text-Based Smoking Cessation Program
for Rural Cancer Survivors
This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.
Recruiting2 awards Phase 3
More about Robin A. Lacour, MD
Clinical Trial Related9 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Robin A. Lacour, MD has experience with
- Carboplatin
- Paclitaxel
- AGEN1884
- AGEN2034
- Everolimus
- Levonorgestrel-Releasing Intrauterine System
Breakdown of trials Robin A. Lacour, MD has run
Endometrial Cancer
Gastroesophageal Junction Adenocarcinoma
Endometrioid Adenocarcinoma
Endometrial Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robin A. Lacour, MD specialize in?
Robin A. Lacour, MD focuses on Endometrial Cancer and Gastroesophageal Junction Adenocarcinoma. In particular, much of their work with Endometrial Cancer has involved Stage III patients, or patients who are Stage IV.
Is Robin A. Lacour, MD currently recruiting for clinical trials?
Yes, Robin A. Lacour, MD is currently recruiting for 2 clinical trials in Loveland Colorado. If you're interested in participating, you should apply.
Are there any treatments that Robin A. Lacour, MD has studied deeply?
Yes, Robin A. Lacour, MD has studied treatments such as Carboplatin, Paclitaxel, AGEN1884.
What is the best way to schedule an appointment with Robin A. Lacour, MD?
Apply for one of the trials that Robin A. Lacour, MD is conducting.
What is the office address of Robin A. Lacour, MD?
The office of Robin A. Lacour, MD is located at: McKee Medical Center, Loveland, Colorado 80539 United States. This is the address for their practice at the McKee Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.